Lightspeed Venture Partners and Ascenta Capital led a $175 Series C round in Alpha-9.

Private equity firms Lightspeed Venture Partners and Ascenta Capital led a $175 Series C round in Alpha-9, a clinical stage company developing radiopharmaceuticals to meaningfully improve the treatment of people living with cancer, with participation from General Catalyst, a16z Bio + Health, RA Capital Management, Janus Henderson Investors, Delos Capital, Digitalis Ventures, Lumira Ventures, abrdn, Frazier Life Sciences, Longitude Capital, Nextech Invest, BVF Partners, and Samsara BioCapital, Shelley Chu and Evan Rachlin. "Over the last few years, Alpha-9 has built a leading radiopharmaceutical company with a deep pipeline and robust infrastructure. The Series C is an exciting, significant milestone for us and will greatly accelerate our growth. We are thrilled to have the backing of a top-tier investor syndicate who share our belief in the potential of radiopharmaceuticals," David Hirsch, Alpha-9 CEO.